Capstan Therapeutics

NEWS
Capstan Therapeutics is looking to move its CAR-T cell candidate forward after securing financing from pharma venture arms and VC firms.
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
With $165 million in the bank, Capstan launched Wednesday to combine the potency of cell therapy with the precision of genetic medicines against various difficult-to-treat diseases.
IN THE PRESS
Capstan Therapeutics, Inc. announced that company management will participate in the upcoming 45th Annual Goldman Sachs Global Healthcare Conference, being held between June 10-13, 2024 at the Loews Miami Beach Hotel in Miami Beach, FL. Capstan will be hosting one-on-one meetings with investors.
Capstan Therapeutics, Inc. today announced the successful closing of a $175M oversubscribed Series B financing.
Capstan Therapeutics, Inc. announced the appointment of Ramin Farzaneh-Far, M.D., as Chief Medical Officer and the promotion of Miguel Arcinas to Senior Vice President, Corporate Development.
Capstan Therapeutics, Inc. today announced it will present preclinical data showing rapid and robust anti-tumor and anti-primary B cell activity in humanized mice by tLNP administration delivering an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR), at the Society for Immunotherapy of Cancer 38th Annual Meeting in San Diego, California.
Capstan Therapeutics, Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles, today announced that the Company’s Co-Founder Drew Weissman, M.D., Ph.D., was awarded the 2023 Nobel Prize in Physiology or Medicine for his discoveries in nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.
Capstan Therapeutics, Inc. today announced that Capstan management will participate in the following upcoming industry conferences.
Capstan Therapeutics, Inc. today announced that Capstan management will participate in the following upcoming investor conferences.
Capstan Therapeutics, Inc. today announced the appointment of Justin Thacker as Chief Financial Officer and Jeffrey Pepe, J.D., Ph.D. as General Counsel.
Capstan Therapeutics, Inc. today announced that Capstan President and Chief Executive Officer, Laura Shawver, Ph.D., will participate in the upcoming Cowen 43rd Annual Health Care Conference, being held between March 6-8, 2023 at the Boston Marriott Copley Place in Boston, MA.
Capstan Therapeutics, Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles, today announced that Capstan management will participate in the upcoming SVB Securities 2023 Global Biopharma Conference, being held virtually between January 31-February 2 and February 13-16, 2023.
AWARDS
  • NextGen Class of 2023